» Articles » PMID: 36243249

Gastrointestinal Symptoms and Complications in Patients Hospitalized Due to COVID-19, an International Multicentre Prospective Cohort Study (TIVURON Project)

Abstract

Background: Retrospective studies suggest that coronavirus disease (COVID-19) commonly involves gastrointestinal (GI) symptoms and complications. Our aim was to prospectively evaluate GI manifestations in patients hospitalized for COVID-19.

Methods: This international multicentre prospective cohort study recruited COVID-19 patients hospitalized at 31 centres in Spain, Mexico, Chile, and Poland, between May and September 2020. Patients were followed-up until 15 days post-discharge and completed comprehensive questionnaires assessing GI symptoms and complications. A descriptive analysis as well as a bivariate and multivariate analysis were performer using binary logistic regression. p<0.05 was considered significant.

Results: Eight hundred twenty-nine patients were enrolled; 129 (15.6%) had severe COVID-19, 113 (13.7%) required ICU admission, and 43 (5.2%) died. Upon admission, the most prevalent GI symptoms were anorexia (n=413; 49.8%), diarrhoea (n=327; 39.4%), nausea/vomiting (n=227; 27.4%), and abdominal pain (n=172; 20.7%), which were mild/moderate throughout the disease and resolved during follow-up. One-third of patients exhibited liver injury. Non-severe COVID-19 was associated with ≥2 GI symptoms upon admission (OR 0.679; 95% CI 0.464-0.995; p=0.046) or diarrhoea during hospitalization (OR 0.531; 95% CI 0.328-0.860; p=0.009). Multivariate analysis revealed that worse hospital outcomes were not independently associated with liver injury or GI symptoms.

Conclusion: GI symptoms were more common than previously documented, and were mild, rapidly resolved, and not independently associated with COVID-19 severity. Liver injury was a frequent complication in hospitalized patients not independently associated with COVID-19 severity.

Citing Articles

Gastrointestinal Tract and Kidney Injury Pathogenesis in Post-COVID-19 Syndrome.

Marzoog B Curr Diabetes Rev. 2023; 20(4):e051023221787.

PMID: 37815187 DOI: 10.2174/0115733998250889230919185305.

References
1.
Wu Y, Guo C, Tang L, Hong Z, Zhou J, Dong X . Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol. 2020; 5(5):434-435. PMC: 7158584. DOI: 10.1016/S2468-1253(20)30083-2. View

2.
Kumar A, Arora A, Sharma P, Anikhindi S, Bansal N, Singla V . Gastrointestinal and hepatic manifestations of Corona Virus Disease-19 and their relationship to severe clinical course: A systematic review and meta-analysis. Indian J Gastroenterol. 2020; 39(3):268-284. PMC: 7399358. DOI: 10.1007/s12664-020-01058-3. View

3.
Shehab M, Alrashed F, Shuaibi S, Alajmi D, Barkun A . Gastroenterological and hepatic manifestations of patients with COVID-19, prevalence, mortality by country, and intensive care admission rate: systematic review and meta-analysis. BMJ Open Gastroenterol. 2021; 8(1). PMC: 7934201. DOI: 10.1136/bmjgast-2020-000571. View

4.
de-Madaria E, Capurso G . COVID-19 and acute pancreatitis: examining the causality. Nat Rev Gastroenterol Hepatol. 2020; 18(1):3-4. PMC: 7670484. DOI: 10.1038/s41575-020-00389-y. View

5.
Parohan M, Yaghoubi S, Seraji A . Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of retrospective studies. Hepatol Res. 2020; 50(8):924-935. PMC: 7273097. DOI: 10.1111/hepr.13510. View